The Association of Post Embryo Transfer SARS-CoV-2 Infection on Early Pregnancy Outcomes in In Vitro Fertilization: A Prospective Cohort Study.

COVID-19 SARS-CoV-2 infection early pregnancy outcome embryo transfer in viro fertilization infertility

Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
20 Dec 2023
Historique:
received: 16 08 2023
revised: 11 12 2023
accepted: 14 12 2023
medline: 23 12 2023
pubmed: 23 12 2023
entrez: 22 12 2023
Statut: aheadofprint

Résumé

The influence of SARS-CoV-2 infection post-embryo transfer on early pregnancy outcomes in in vitro fertilization (IVF) or intracytoplasmic sperm injection-embryo transfer (ICSI-ET) treatment remains inadequately understood. This knowledge gap endures despite an abundance of studies investigating the repercussions of preceding SARS-CoV-2 infection on early pregnancy outcomes in spontaneous pregnancies. Our objective was to investigate the association between SARS-CoV-2 infection within 10 weeks post-embryo transfer and early pregnancy outcomes in patients undergoing IVF/ICSI treatment. This prospective cohort study was conducted at a single public IVF center in China. Female patients aged 20 to 39 years, with a body mass index (BMI) ranging from 18 to 30 kg/m A total of 857 female patients undergoing IVF/ICSI treatment were analyzed. In the first stage, SARS-CoV-2 infection within 14 days post-embryo transfer did not exhibit a significant negative association with the biochemical pregnancy rate (adjusted OR 0.74, 95% CI, 0.51-1.09). In the second stage, SARS-CoV-2 infection within 28 days post-embryo transfer revealed no significant difference in the implantation rate between infected and uninfected groups (36.6% vs 44.0%, p=0.181), and the clinical pregnancy rate showed no statistical significance after adjusting for confounding factors (adjusted OR, 0.69, 95% CI, 0.56-1.09). In the third stage, SARS-CoV-2 infection within 10 weeks post-embryo transfer showed no significant difference in the early miscarriage rate (adjusted OR, 0.77, 95% CI, 0.35-1.71). Our study suggested that SARS-CoV-2 infection within 10 weeks after embryo transfer may not be negatively associated with the biochemical pregnancy rate, implantation rate, clinical pregnancy rate, and early miscarriage rate in patients undergoing IVF/ICSI treatment. It's important to note that these findings are specific to the target population of IVF/ICSI patients aged 20-39 years, without prior SARS-CoV-2 infection, and with a BMI of 18-30 kg/m

Sections du résumé

BACKGROUND BACKGROUND
The influence of SARS-CoV-2 infection post-embryo transfer on early pregnancy outcomes in in vitro fertilization (IVF) or intracytoplasmic sperm injection-embryo transfer (ICSI-ET) treatment remains inadequately understood. This knowledge gap endures despite an abundance of studies investigating the repercussions of preceding SARS-CoV-2 infection on early pregnancy outcomes in spontaneous pregnancies.
OBJECTIVE OBJECTIVE
Our objective was to investigate the association between SARS-CoV-2 infection within 10 weeks post-embryo transfer and early pregnancy outcomes in patients undergoing IVF/ICSI treatment.
STUDY DESIGN METHODS
This prospective cohort study was conducted at a single public IVF center in China. Female patients aged 20 to 39 years, with a body mass index (BMI) ranging from 18 to 30 kg/m
RESULTS RESULTS
A total of 857 female patients undergoing IVF/ICSI treatment were analyzed. In the first stage, SARS-CoV-2 infection within 14 days post-embryo transfer did not exhibit a significant negative association with the biochemical pregnancy rate (adjusted OR 0.74, 95% CI, 0.51-1.09). In the second stage, SARS-CoV-2 infection within 28 days post-embryo transfer revealed no significant difference in the implantation rate between infected and uninfected groups (36.6% vs 44.0%, p=0.181), and the clinical pregnancy rate showed no statistical significance after adjusting for confounding factors (adjusted OR, 0.69, 95% CI, 0.56-1.09). In the third stage, SARS-CoV-2 infection within 10 weeks post-embryo transfer showed no significant difference in the early miscarriage rate (adjusted OR, 0.77, 95% CI, 0.35-1.71).
CONCLUSION CONCLUSIONS
Our study suggested that SARS-CoV-2 infection within 10 weeks after embryo transfer may not be negatively associated with the biochemical pregnancy rate, implantation rate, clinical pregnancy rate, and early miscarriage rate in patients undergoing IVF/ICSI treatment. It's important to note that these findings are specific to the target population of IVF/ICSI patients aged 20-39 years, without prior SARS-CoV-2 infection, and with a BMI of 18-30 kg/m

Identifiants

DOI: 10.1016/j.ajog.2023.12.022 PMID: 38135094
pubmed: 38135094
pii: S0002-9378(23)02171-3
doi: 10.1016/j.ajog.2023.12.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Xue-Fei Li (XF)

The Reproductive Center, Sichuan Jinxin Xinan Women and Children's Hospital, Chengdu 610011, Sichuan, China.

Yong-Jia Zhang (YJ)

Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing 401147, China; Joint International Research Laboratory of Reproduction and Development of the Ministry of Education of China, School of Public Health, Chongqing Medical University, Chongqing 400016, China.

Ying-Ling Yao (YL)

Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing 401147, China; Joint International Research Laboratory of Reproduction and Development of the Ministry of Education of China, School of Public Health, Chongqing Medical University, Chongqing 400016, China.

Ming-Xing Chen (MX)

Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing 401147, China; Joint International Research Laboratory of Reproduction and Development of the Ministry of Education of China, School of Public Health, Chongqing Medical University, Chongqing 400016, China.

Li-Li Wang (LL)

The Reproductive Center, Sichuan Jinxin Xinan Women and Children's Hospital, Chengdu 610011, Sichuan, China.

Meng-Di Wang (MD)

Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing 401147, China; Joint International Research Laboratory of Reproduction and Development of the Ministry of Education of China, School of Public Health, Chongqing Medical University, Chongqing 400016, China.

Xin-Yue Hu (XY)

Joint International Research Laboratory of Reproduction and Development of the Ministry of Education of China, School of Public Health, Chongqing Medical University, Chongqing 400016, China.

Xiao-Jun Tang (XJ)

Joint International Research Laboratory of Reproduction and Development of the Ministry of Education of China, School of Public Health, Chongqing Medical University, Chongqing 400016, China.

Zhao-Hui Zhong (ZH)

Joint International Research Laboratory of Reproduction and Development of the Ministry of Education of China, School of Public Health, Chongqing Medical University, Chongqing 400016, China.

Li-Juan Fu (LJ)

Joint International Research Laboratory of Reproduction and Development of the Ministry of Education of China, School of Public Health, Chongqing Medical University, Chongqing 400016, China; Department of Pharmacology, Academician Workstation, Changsha Medical University, Changsha 410219, China.

Xin Luo (X)

Department of Obstetrics and Gynecology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

Xing-Yu Lv (XY)

The Reproductive Center, Sichuan Jinxin Xinan Women and Children's Hospital, Chengdu 610011, Sichuan, China.

Li-Hong Geng (LH)

The Reproductive Center, Sichuan Jinxin Xinan Women and Children's Hospital, Chengdu 610011, Sichuan, China.

Qi Wan (Q)

Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu 610041, Sichuan, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, Sichuan, China. Electronic address: wanqi123@163.com.

Yu-Bin Ding (YB)

Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing 401147, China; Joint International Research Laboratory of Reproduction and Development of the Ministry of Education of China, School of Public Health, Chongqing Medical University, Chongqing 400016, China. Electronic address: dingyb@cqmu.edu.cn.

Classifications MeSH